Cytomegalovirus Retinitis, HIV Infections
Conditions
Keywords
Retinitis, Ganciclovir, Cytomegalovirus Infections, Administration, Oral, Acquired Immunodeficiency Syndrome
Brief summary
To compare the safety and tolerance of oral ganciclovir at a double dose 3 times/day or a single dose 6 times/day to IV ganciclovir given for 20 weeks of maintenance therapy. To compare the time to progression of cytomegalovirus (CMV) retinitis between two regimens of oral ganciclovir and IV ganciclovir therapy given for 20 weeks of maintenance therapy. To describe the efficacy and safety of double dose versus single dose oral ganciclovir in patients who have a progression of retinitis while on the originally assigned maintenance treatment. To describe the safety, tolerance, and time to progression of retinitis during the 52 weeks of oral ganciclovir maintenance therapy in people with AIDS. To describe the safety and tolerance of oral ganciclovir maintenance therapy when given concurrently with antiretroviral treatment (e.g., zidovudine, ddI, or ddC). To describe survival of people with AIDS and CMV retinitis.
Detailed description
Two hundred twenty-five patients with AIDS and CMV retinitis are eligible for enrollment in Groups A, B, and C of the study, provided that each subject has received and tolerated a therapeutic course of intravenous (IV) ganciclovir of at least 4 weeks duration resulting in stable retinitis. An additional 100 subjects who have received and tolerated a course of IV or oral ganciclovir under any clinical trial of oral ganciclovir sponsored by Syntex Research and have stable retinitis may enter into Group D of this study and receive oral ganciclovir.
Interventions
DRUGGanciclovir
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: * Zidovudine except during the first 2 weeks of any oral or IV ganciclovir maintenance therapy. * ddI. * ddC. Patients must have: * Confirmed HIV infection or diagnosis of AIDS. * CMV retinitis of no more than 4 months duration. * Stable retinitis. * Understanding of the nature of the study, agree to its provisions, and sign informed consent.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Persistent or clinically significant diarrhea (3 or more unformed stools/day), nausea, or abdominal pain or other gastrointestinal symptoms or uncontrolled gastrointestinal disease. * Ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic retinal assessment. * Ocular conditions requiring immediate surgical correction (e.g., retinal tear or detachment). * Dementia, decreased mentation, or other encephalopathic signs and symptoms that would interfere with the ability of the subject to give informed consent or comply with the protocol. Concurrent Medication: Excluded: * Zidovudine during the first 2 weeks of any oral or IV ganciclovir maintenance therapy. * Antimetabolites. * Alkylating agents. * Selected nucleoside analogs. * Selected cytokines. Patients with the following prior conditions are excluded: * Diagnosis of CMV retinitis more than 4 months prior to study entry. * More than two prior induction treatments of IV ganciclovir (initial induction and one re-induction are permitted). Prior Medication: Excluded: * More than two induction treatment regimens with IV ganciclovir. * Prior oral ganciclovir (in Groups A, B, and C only).
Countries
Canada, United States
Outcome results
None listed